The Protagen® Multilisa® BICD2 is a CE-approved IVD ELISA for the semi-quantitative determination of antibodies specific for the BICD2 protein in human serum and plasma. The results of the Multilisa® BICD2 together with the assessment of clinical symptoms are used in the diagnosis of Systemic Sclerosis (SSc) and can enable patient stratification into disease sub-types.
BICD2 - A novel, proprietary biomarker for SSc diagnosis
The newly discovered anti-BICD2 autoantibodies are found in approximately 30% of patients with SSc and are highly associated with limited forms of SSc. Beyond the classical markers such as CENP-B and Scl-70, BICD2 is the most abundant target of autoantibodies in patients with SSc.
BICD2 is also an evolutionarily conserved motor adaptor protein that is involved in dynein-mediated transport process. Anti BICD-2 antibodies appear to correlate with a mild disease-course of SSc. In a recent study anti-BICD-2 autoantibodies were found predominantly in patients without lung fibrosis. It is the detection of these differential levels of BICD2 autoantibodies, when used alongside other diagnostic markers that can allow for the differential diagnosis of SSc patients and facilitate a more personalised therapeutic regimen for specific SSc patient groups.
Application of the proprietary BICD2 biomarker to a CE-approved IVD assay
The new Multilisa® BICD2 assay has received CE certification and is a market-ready IVD product available for purchase within the EU. If you would like to place an order or gather further information on Multilisa® BICD2 please contact our team by filling in the form on the right.